Shots:

• The US FDA has granted BTD for disitamab vedotin (RC48) for 2L treatment patients with HER2+ LA/m-UC who had prior received Pt-containing CT treatment
• Earlier- RemeGen reported the FDA's clearance of an IND application for a P-II clinical study in the US and the grant of FTD for disitamab vedotin
• RC48 is a novel humanized anti-HER2 ADC- currently being studied in multiple late-stage clinical trials across solid tumor types

 ­ Ref: PRNewswire | Image: PRNewswire